Clinical trials: Erythropoietin
Anemia, Kidney Disease, Chronic
A Study of The Effect of Altitude on Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) Dose Requirements in Participants With Chronic Renal Anemia in Pre-Dialysis or Dialysis
This comparative, open-label, multicenter, parallel-group study evaluated the effect of altitude on the dose requirements of Mircera (methoxy polyethylene glycol-epoetin beta) to achieve a target hemoglobin concentration of 11-12…
- Trial name
- ALTITUD (NCT01519947)
- Testing
- Methoxy polyethylene glycol-epoetin beta
- Where
- 7 sites in Mexico
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Anemia
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
The purpose of this study is to compare hemoglobin response rates between two PROCRIT (epoetin alfa) doses and ARANESP (darbepoetin alfa) in anemic cancer patients receiving chemotherapy
- Conditions
- Neoplasms, Anemia, Cancer
- Trial name
- NCT00386152
- Testing
- epoetin alfa, darbepoetin alfa
- Where
- 76 sites in United States
- Volunteers
- 235 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Chronic Kidney Disease
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure, Cancer
- Trial name
- NCT00097747
- Testing
- peginesatide
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Affymax
Chronic Hepatitis C
High Dose Ribavirin in the Treatment of Chronic Hepatitis C
Treatment of patients with chronic hepatitis C infected with genotype 1 hepatitis C virus (HCV) consists of combined peginterferon/ribavirin for 48 weeks.
- Trial name
- NCT00944684
- Testing
- High ribavirin dose, Standard ribavirin dose
- Where
- 5 sites in Switzerland
- Volunteers
- 32 people
- Sponsor
- University of Bern
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pre-dialysis, End Stage Renal Disease
NESP Pediatric Study
Open-label, randomized study of NESP in pediatric subjects 18 years of age or younger. Subjects will receive study drug (NESP or rHuEPO) for 28 weeks after a 2 week screening and baseline period.
- Trial name
- NCT00527137
- Testing
- darbepoetin alfa, rHuEPO
- Volunteers
- 120 people
- Sponsor
- Amgen
Renal Anemia of Chronic Kidney Disease
Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia
This study is to document the time spent by health care personnel on anemia-related tasks, including preparation, distribution and administration of monopegylated epoetin beta (Mircera) or other erythropoiesis-stimulating agents…
- Trial name
- NCT02625844
- Testing
- No intervention
- Where
- 4 sites in Croatia
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Perinatal Asphyxia
Neuroprotective Role of Erythropoietin in Perinatal Asphyxia
Whether Erythropoietin improves the neurological outcomes of neonates with perinatal asphyxia.
- Trial name
- NCT02002039
- Testing
- Erythropoietin
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Sheri Kashmir Institute of Medical Sciences
Kidney Failure
Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant
Main objective : Assessing the effect of epoetin beta on Hb rate and the glomerular filtration rate estimated 30 days after kidney transplant.
- Trial name
- Neo-PDGF (NCT00815867)
- Testing
- epoetin beta (NeoRecormon ®)
- Where
- 17 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Renal Insufficiency, Chronic
Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells.
- Trial name
- NCT03572647
- Testing
- Eritromax, Eprex
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Prostate, Carcinoma
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
The purpose of this study was to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) or placebo on anemia related quality-of-life and anemia in hormone-refractory (not responding to hormone…
- Trial name
- NCT00364455
- Testing
- Epoetin alfa
- Volunteers
- 56 people
- Sponsor
- Janssen-Ortho Inc., Canada
Myelodysplastic Syndromes
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)
This is a Phase IV, prospective, multi-center, open-label study to assess the effectiveness and safety profile of epoetin beta (Recormon®) for treatment of symptomatic anemia in adult participants associated with…
- Trial name
- NCT02145026
- Testing
- Epoetin beta
- Where
- 10 sites in Thailand
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Sepsis, Shock
The Effect of Erythropietin on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis
The objective of this study is to determine if observations the investigators made in an animal model of sepsis can be translated to clinical practice.
- Trial name
- NCT01087450
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- London Health Sciences Centre
Anemia, Kidney Diseases
Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.
The purpose of this study is to evaluate the hemoglobin response rate in subjects with anemia, associated with chronic kidney failure, after receiving epoetin alfa (PROCRIT®) every 2 weeks
- Trial name
- NCT00210743
- Testing
- epoetin alfa
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy
Identifying Biological Markers for Altitude Exposure and Use of Recombinant Human Erythropoietin (rHuEPO)
The project represents a well powered study of the human response to altitude exposure combined with rHuEPO treatment. A total of 20 male and 20 female non-competing athletes will participate.
- Trial name
- NCT04227665
- Testing
- Sea level, Altitude
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Anemia, Aged
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
The purpose of this study is to assess changes in physical function in elderly patients (>= 65 years of age) with chronic anemia (Hb <= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin…
- Conditions
- Anemia, Aged, Hemoglobins
- Trial name
- NCT00210795
- Testing
- epoetin alfa
- Volunteers
- 12 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Myelodysplastic Syndromes
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at…
- Trial name
- COMMANDS (NCT03682536)
- Testing
- Luspatercept, Epoetin alfa
- Where
- 226 sites in United States, Australia and 24 more
- Volunteers
- 363 people
- Sponsor
- Celgene
Trauma, Traumatic Injury
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in…
- Conditions
- Trauma, Traumatic Injury, Traumatic Brain Injury, Wounds and Injuries
- Trial name
- EPO-TRAUMA (NCT04588311)
- Testing
- Epoetin Alfa 40000 UNT/ML, Sodium Chloride 0.9%
- Where
- 41 sites in Australia, Belgium and 7 more
- Volunteers
- 2,500 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Chronic Kidney Disease, Anemia
Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
The primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.
- Trial name
- NCT01244763
- Testing
- Roxadustat
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 145 people
- Sponsor
- Kyntra Bio
Traumatic Brain Injury
Erythropoietin Effects After Traumatic Brain Injury
To determine if the early administration of erythropoietin to patients sustaining traumatic brain injury will reduce secondary brain injury.
- Trial name
- NCT00260052
- Testing
- Erythropoietin administration
- Where
- United States
- Sponsor
- Medical College of Wisconsin